Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years
source: Journal of Genetic Counseling
year: 2016
authors: Gallo AM, Wilkie DJ, Yao Y, Molokie RE, Stahl C, Hershberger PE, Zhao Z, Suarez ML, Johnson B, Angulo R, Carrasco J, Angulo V, Thompson AA
summary/abstract:Interventions to assist reproductive health decision-making in populations affected by sickle cell disease (SCD) or trait (SCT) lack proven efficacy over time. Our aim was to compare effects of CHOICES, a Web-based multimedia education program on implementing informed reproductive plans, and usual care education (e-Book) on reproductive knowledge, intention, and behavior over 24 months. We randomized 234 participants with SCD (n = 138) or SCT (n = 96) (age 18-35 years, 35 % male, 94 % African American) to CHOICES and e-Book groups. Participants completed a sickle cell-specific reproductive measure before and four times after the intervention (6, 12, 18 and 24 months). Compared to the e-Book group the CHOICES group had significantly more improvement in knowledge over time (p = .004) but not intention (p = .18) or behavior (p = .69). At baseline, 114 (48.7 %) participants reported having partners who would not put the couple at risk for their children inheriting SCD. Of the 116 (49.6 %) at-risk participants, a higher poroportion of those who were in the CHOICES group chose partners that reduced their risk by the last visit than the e-Book group (p = .04). Study findings provide important insights for designing a national trial of the CHOICES intervention focusing on subjects whose partner status puts them at risk for having a child with SCD.
organization: University of Illinois at Chicago; University of Florida; Jesse Brown Veterans Administration Medical Center, Chicago; Ann and Robert H. Lurie Children's Hospital of Chicago; Northwestern University-Feinberg School of Medicine, ChicagoDOI: 10.1007/s10897-015-9874-0
read more full text
Related Content
-
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Depende...First patient with severe sickle cell di...
-
Women with Sickle Cell Disease and Preconception Care: What to Know Before Getting PregnantWhether you are planning to get pregnant...
-
Young Sickle Cell Patients Who Don’t Take Medication Have Lower Quality of LifeAdolescents and young adults with sickle...
-
8th Annual Leadership Summit and General Assembly of Patients, Caregivers & CBOsThe Sickle Cell Consortium (SC3) announc...
-
School staff lacks knowledge about sickle cell disease, student survey findsStudents with sickle cell dise...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Sickle cell disease in childrenSickle cell disease (SCD) is an inherite...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
+myBinder